Genetics & Epigenetics Library
Every article, presentation, spotlight, and news item we've tagged to Genetics & Epigenetics.
Showing 73–96 of 176
AI-Engineered T-Cell Therapy Targets Cancer Precision
METiS TechBio licensed MTS-128, a trispecific T-cell engager designed through AI-driven protein engineering, to Boulevard Bio for up to $1.6 billion in milestone payments. The transaction represents commercialization of AI-optimized immunotherapy targeting cancer, where precision T-cell engagement directly impacts survival outcomes in difficult-to-treat malignancies.
Research Worth Sharing, April 2026 Edition
Four emerging research areas—paternal exercise effects on offspring via sperm signaling molecules, mRNA vaccine applications in cancer treatment, non-invasive sensory stimulation for neurodegeneration, and autonomic nervous system dysfunction as a common aging mechanism—establish mechanistic pathways through which upstream interventions influence downstream health outcomes across generations and disease states.
GenSight Biologics updates early access programs for LUMEVOQ therapy
GenSight Biologics is advancing LUMEVOQ (GS010), a gene therapy targeting ND4 mitochondrial mutations in Leber hereditary optic neuropathy, through early access programs in France, Israel, and the United States while conducting the REVISE dose-ranging clinical study. This represents progress toward treating a rare genetic form of progressive vision loss by addressing the underlying mitochondrial dysfunction.
ALS therapeutics landscape projects growth through 2035
The global ALS therapeutics market is projected to more than double from $812 million in 2024 to $1.964 billion by 2035, driven by innovation in disease-modifying and neuroprotective approaches including antisense oligonucleotides, gene therapies, and biologics. This expansion reflects a fundamental shift in treatment philosophy from symptomatic management toward interventions that address underlying neurodegeneration.
GBA1 mutations drive Parkinson's progression via lysosomal trafficking
Harness Therapeutics received funding to develop a microRNA-based therapeutic targeting glucocerebrosidase and lysosomal protein trafficking in GBA1-associated Parkinson's disease, addressing the most common genetic risk factor for the condition. This approach represents a shift toward disease modification rather than symptom management in a significant subset of Parkinson's patients.
PNPLA3-Targeted RNA Therapy Cuts Liver Fat 46% in MASH
Madrigal acquired exclusive global rights to ARO-PNPLA3, an RNA interference therapy targeting PNPLA3 mutations that drive metabolic dysfunction-associated steatohepatitis. Phase 1 data demonstrated 46% reduction in liver fat within 12 weeks in genetically defined patients, establishing a precision-medicine approach to a disease affecting millions with limited treatment options.
Alnylam reports strong 2025 revenue growth and profitability
This article reports Alnylam Pharmaceuticals' 2025 financial performance—$2.987 billion in annual revenue with 81% year-over-year growth and achievement of profitability. The financial success reflects commercial adoption of RNA interference therapeutics for rare genetic and cardiometabolic diseases, which has direct relevance to the development and accessibility of precision therapies that address underlying genetic drivers of age-related conditions.
Biological age tests reveal what slows or hastens aging – but they’re useful only for researchers, not consumers
Epigenetic aging clocks measure chemical changes to DNA to estimate biological age, but they are research tools designed for population-level study, not reliable for individual health assessment. Consumer products marketing these tests as personal health indicators misrepresent their validity and clinical utility.
When Doctors Prescribe Horoscopes: The Trouble With Biological Age Tests
Commercially available biological age tests based on epigenetic markers lack clinical validity, standardized accuracy measures, and actionable clinical utility. When physicians recommend them, they abandon evidence-based practice in favor of customer satisfaction, potentially replacing genuine health assessment with unfounded reassurance or unnecessary anxiety.
Biological clocks age within a day without you aging!
Biological age clocks derived from DNA methylation patterns show significant day-to-day fluctuations within individuals, independent of actual chronological aging. This instability raises critical questions about their reliability for clinical application and longevity intervention assessment.
Methylation mapping links aging pathways to disease risk
Researchers have developed an interpretable epigenetic clock that maps DNA methylation patterns to specific aging pathways and disease profiles, enabling prediction of biological age and disease risk with greater mechanistic clarity. This advances the capacity to distinguish between chronological aging and disease-driven methylation changes, offering a more precise tool for identifying which physiological systems are accelerating in individual patients.
Klotho unveils AI-powered aging clock
Klotho Neurosciences has developed AI-powered genomics tests that measure biological age through DNA methylation and mRNA analysis of longevity-associated genes. This approach enables more precise stratification in clinical trials for neurodegenerative diseases, reducing confounding variables that arise when chronological and biological age diverge.
Epigenetic clocks measure drift, not aging itself
Epigenetic clocks quantify the cumulative drift in DNA methylation patterns that occurs with aging, yet their functional relationship to aging outcomes remains poorly defined. Understanding what these clocks actually measure—rather than assuming they capture aging itself—is essential for interpreting their clinical utility in longevity assessment.
Epigenetic aging signatures unlock precision intervention pathways
Epigenetic clocks measure aging at the molecular level by tracking DNA methylation patterns and gene expression changes. Decoding these signatures reveals specific biological pathways driving accelerated aging, enabling targeted interventions before functional decline becomes apparent.
OMICmAge is a multiomic biological aging clock using electronic medical records
Researchers developed OMICmAge, a DNA-methylation-based biological aging clock integrating proteomic and metabolomic data from 31,000 electronic medical records. The measure predicts mortality and age-related disease risk with performance comparable to or superior to existing biomarkers, offering a scalable tool for quantifying biological aging status.
OMICmAge quantifies biological age by integrating multi-omics with electronic medical records
OMICmAge integrates multi-omics data with DNA methylation to create a biological age measure that predicts disease and mortality risk more accurately than chronological age alone. This approach enables risk stratification based on measurable molecular signatures rather than calendar years.
Sex-Specific Biological Age Test Quantifies Organ Aging and Treatment Response
Generation Lab released SystemAge 2.1, a biological age test measuring 460+ biomarkers across 21 organ systems with sex-specific analysis and 99% validated accuracy. The platform tracks organ-level aging trajectories and quantifies treatment response to interventions including stem cells and plasma exchange, enabling practitioners to detect accelerated aging earlier and monitor intervention efficacy with precision.
Gene Expression Aging Clock Simplifies Intervention Testing
Researchers have developed Pasta, a transcriptomic clock that measures age-related changes through gene expression patterns rather than DNA methylation. This tool addresses limitations in existing epigenetic clocks by offering a more accessible method to assess how interventions affect biological aging at the molecular level.
Longitudinal changes in epigenetic clocks predict long-term mortality
Longitudinal changes in epigenetic clocks—molecular markers of biological age—independently predict mortality over 24 years, independent of baseline biological age. This establishes that the rate of epigenetic change itself, not just absolute age status, carries clinically actionable information for longevity assessment.
Biological Noise Limits Epigenetic Clock Accuracy
Methylation-based epigenetic clocks demonstrate technical reliability but are vulnerable to short-term biological fluctuations that alter their outputs. This distinction between measurement consistency and biological stability has direct implications for using these clocks as aging biomarkers and intervention validators in clinical practice.
Genetic and molecular factors underlying human longevity and epigenetic aging
Epigenetic aging—the divergence between chronological age and biological age—emerges as a measurable marker influenced by both genetic predisposition and modifiable molecular factors. Understanding these mechanisms provides actionable insight into why some individuals age more slowly at the cellular level and how interventions targeting epigenetic signatures may extend healthspan.
DeepStrataAge: an interpretable deep-learning clock that reveals stage- and sex-divergent DNA methylation aging dynamics
DeepStrataAge, a deep-learning model trained on DNA methylation patterns, identifies distinct aging trajectories between biological sexes and developmental stages, revealing that aging acceleration is not uniform across the lifespan. This sex- and stage-specific resolution improves the precision of biological age assessment and may refine risk stratification for age-related disease prevention.
Epigenetic aging and cancer incidence in a German cohort of older adults
Epigenetic age acceleration—measured through DNA methylation patterns—independently predicts cancer incidence in older adults, even after accounting for chronological age and established risk factors. This biomarker offers a quantifiable proxy for biological aging that may identify individuals at elevated cancer risk before conventional screening protocols would.
Blood protein clocks reveal true aging rate in populations
Blood protein signatures can now quantify biological aging with precision previously available only through complex genetic testing. Proteomic aging clocks measure the rate at which your body's protein landscape diverges from healthy baselines, offering a practical biomarker for assessing longevity risk and intervention responsiveness in large population studies.